PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1735778
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1735778
Global Anti-malarial Drugs Market Size study, by Drug Class, Malaria Type, and Mechanism of Action and Regional Forecasts 2022-2032
Global Anti-malarial Drugs Market is valued approximately at USD 0.98 billion in 2023 and is anticipated to grow with a moderate but promising CAGR of more than 4.26% over the forecast period 2024-2032. In the enduring fight against malaria, anti-malarial drugs serve as critical lifelines for millions of people in endemic regions across the globe. These therapeutics are engineered to either eliminate the parasite after infection or prevent it from developing in the human body altogether. The expanding footprint of climate-sensitive mosquito-borne diseases, coupled with cross-border population migration and inadequate sanitation infrastructure, has elevated the urgency for advanced, accessible, and durable anti-malarial treatment protocols.
Recent years have seen a revival in innovation pipelines, driven by international funding coalitions and public-private partnerships such as Medicines for Malaria Venture (MMV) and WHO-led eradication roadmaps. Drug development has leaned toward novel artemisinin-based combination therapies (ACTs) and next-generation antifolates aimed at combating Plasmodium falciparum and emerging drug-resistant strains. Pharmaceutical companies are also exploring single-dose and long-acting agents that can curtail compliance issues in vulnerable populations. However, concerns over growing parasite resistance and high R&D costs pose significant challenges to both scalability and market penetration.
The market is not just shaped by treatment dynamics but also by the growing use of anti-malarials for prophylactic applications among travelers, military personnel, and humanitarian workers. There's increasing focus on the stratification of treatment based on malaria species-P. falciparum, P. vivax, P. malariae, and P. ovale-due to their varying virulence, recurrence patterns, and geographical spread. Moreover, the demand for pediatric and pregnant-safe formulations is prompting players to diversify product portfolios while ensuring regulatory compliance across emerging economies with high disease burdens.
Regionally, Africa continues to dominate the anti-malarial drugs market, being the epicenter of the global malaria burden. Countries such as Nigeria and the Democratic Republic of Congo account for a disproportionately high percentage of global cases, making them hotspots for treatment and prevention interventions. Asia Pacific is also expanding rapidly due to intensified governmental campaigns in India, Myanmar, and Indonesia, alongside heightened deployment of ACTs. Meanwhile, Latin America is witnessing re-emergence pockets in countries like Venezuela and Brazil due to migration-linked transmission. North America and Europe maintain steady market shares primarily through prophylactic sales and research activities driven by traveler-based demand and institutional collaborations.
Major market player included in this report are:
- Novartis AG
- Cipla Ltd.
- Sanofi S.A.
- GlaxoSmithKline plc
- Mylan N.V.
- Pfizer Inc.
- Ipca Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Zydus Lifesciences Limited
- Strides Pharma Science Ltd.
- Hikma Pharmaceuticals PLC
- Torrent Pharmaceuticals Ltd.
The detailed segments and sub-segment of the market are explained below:
By Drug Class
- Aryl Amino Alcohol Compounds
- Antifolate Compounds
- Artemisinin Compounds
- Other Drug Types
By Malaria Type
- Plasmodium Falciparum
- Plasmodium Vivax
- Plasmodium Malarie
- Plasmodium Ovale
By Mechanism of Action
- Treatment for Malaria
- Prevention from Malaria
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Anti-malarial Drugs Market Executive Summary
- 1.1. Global Anti-malarial Drugs Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Drug Class
- 1.3.2. By Malaria Type
- 1.4. Key Trends
- 1.5. Treatment vs. Prevention Mix
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Anti-malarial Drugs Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Manufacturing Capacity
- 2.3.3.2. API Sourcing & Quality
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Cost Structures
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Public Health Policies
- 2.3.4.2. Diagnostic Access
- 2.3.4.3. Patient Compliance
- 2.3.4.4. Awareness & Education
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Anti-malarial Drugs Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Rising Malaria Prevalence in Endemic Regions
- 3.1.2. International Funding & Public-Private Partnerships
- 3.1.3. Growth in Prophylactic Use among Travelers and Military
- 3.2. Market Challenges
- 3.2.1. Emergence of Drug-Resistant Parasite Strains
- 3.2.2. High R&D and Clinical Trial Costs
- 3.3. Market Opportunities
- 3.3.1. Development of Long-Acting Single-Dose Therapies
- 3.3.2. Expansion of Pediatric and Pregnancy-Safe Formulations
- 3.3.3. Digital Distribution and Tele-medicine Initiatives
Chapter 4. Global Anti-malarial Drugs Market Industry Analysis
- 4.1. Porter's Five Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Future Outlook on Five Forces
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunities
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspectives
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Anti-malarial Drugs Market Size & Forecasts by Drug Class 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Anti-malarial Drugs Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Aryl Amino Alcohol Compounds
- 5.2.2. Antifolate Compounds
- 5.2.3. Artemisinin Compounds
- 5.2.4. Other Drug Types
Chapter 6. Global Anti-malarial Drugs Market Size & Forecasts by Malaria Type 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Anti-malarial Drugs Market: Malaria Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Plasmodium Falciparum
- 6.2.2. Plasmodium Vivax
- 6.2.3. Plasmodium Malarie
- 6.2.4. Plasmodium Ovale
Chapter 7. Global Anti-malarial Drugs Market Size & Forecasts by Region 2022-2032
- 7.1. North America Anti-malarial Drugs Market
- 7.1.1. U.S. Anti-malarial Drugs Market
- 7.1.1.1. Drug Class breakdown, 2022-2032
- 7.1.1.2. Malaria Type breakdown, 2022-2032
- 7.1.2. Canada Anti-malarial Drugs Market
- 7.1.1. U.S. Anti-malarial Drugs Market
- 7.2. Europe Anti-malarial Drugs Market
- 7.2.1. UK Anti-malarial Drugs Market
- 7.2.2. Germany Anti-malarial Drugs Market
- 7.2.3. France Anti-malarial Drugs Market
- 7.2.4. Spain Anti-malarial Drugs Market
- 7.2.5. Italy Anti-malarial Drugs Market
- 7.2.6. Rest of Europe Anti-malarial Drugs Market
- 7.3. Asia-Pacific Anti-malarial Drugs Market
- 7.3.1. China Anti-malarial Drugs Market
- 7.3.2. India Anti-malarial Drugs Market
- 7.3.3. Japan Anti-malarial Drugs Market
- 7.3.4. Australia Anti-malarial Drugs Market
- 7.3.5. South Korea Anti-malarial Drugs Market
- 7.3.6. Rest of Asia Pacific Anti-malarial Drugs Market
- 7.4. Latin America Anti-malarial Drugs Market
- 7.4.1. Brazil Anti-malarial Drugs Market
- 7.4.2. Mexico Anti-malarial Drugs Market
- 7.4.3. Rest of Latin America Anti-malarial Drugs Market
- 7.5. Middle East & Africa Anti-malarial Drugs Market
- 7.5.1. Saudi Arabia Anti-malarial Drugs Market
- 7.5.2. South Africa Anti-malarial Drugs Market
- 7.5.3. Rest of Middle East & Africa Anti-malarial Drugs Market
Chapter 8. Competitive Intelligence
- 8.1. Key Company SWOT Analysis
- 8.1.1. Novartis AG
- 8.1.2. Cipla Ltd.
- 8.1.3. Sanofi S.A.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
- 8.3.1. Novartis AG
- 8.3.1.1. Key Information
- 8.3.1.2. Overview
- 8.3.1.3. Financial (Subject to Data Availability)
- 8.3.1.4. Product Summary
- 8.3.1.5. Market Strategies
- 8.3.2. Cipla Ltd.
- 8.3.3. Sanofi S.A.
- 8.3.4. GlaxoSmithKline plc
- 8.3.5. Mylan N.V.
- 8.3.6. Pfizer Inc.
- 8.3.7. Ipca Laboratories Ltd.
- 8.3.8. Sun Pharmaceutical Industries Ltd.
- 8.3.9. Amneal Pharmaceuticals, Inc.
- 8.3.10. Teva Pharmaceutical Industries Ltd.
- 8.3.1. Novartis AG
Chapter 9. Research Process
- 9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes
